Publications by authors named "E Michna"
Objective: Methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, alleviates opioid-induced constipation. Understanding its long-term safety and efficacy profile in patients with chronic noncancer pain is warranted given the persistence of opioid-induced constipation.
Methods.
Article Synopsis
- - The study examined anesthesia-related liability claims linked to implantable pain management devices, finding that there were 148 claims from 1990 onward involving various damaging events like medication errors and infections.
- - The most prevalent devices were implantable drug delivery systems (IDDS) and spinal cord stimulators, with IDDS maintenance claims resulting in more severe injuries (56% leading to death or permanent damage) compared to surgical device procedure claims (26%).
- - Major causes of harm in IDDS maintenance were medication errors and failure to identify granuloma formation, while surgical procedures mainly faced issues like infections and inadequate pain relief; thus, careful management of these devices is essential to prevent patient risks.
Objective: Opioids are frequently prescribed for chronic low back pain (CLBP), but there are broad individual differences in the benefits and risks of opioid therapy, including the development opioid-induced hyperalgesia. This study examined quantitative sensory testing (QST) data among a group of CLBP patients undergoing sustained oral opioid treatment. We investigated whether individual differences in psychological characteristics were related to opioid-induced changes in pain perception and pain modulation.
View Article and Find Full Text PDFBackground: A previous 52-week trial of patients with chronic noncancer, non-neuropathic pain (CNNP) showed clinically meaningful improvement in pain intensity, pain interference, and physical health-related quality of life (HRQL) following daily treatment with an extended-release, once-daily hydrocodone (Hysingla(®) ER; HYD) bitartrate tablet.
Objective: To examine treatment response within patient subgroups and to assess between-subgroup differences in effectiveness and side effect profile.
Methods: Data were from an open-label 52-week trial of treatment with HYD tablets (20-120 mg, once-daily) for patients with moderate-to-severe CNNP.
Background: There is abundant literature on the long-term complications of intrathecal pumps (ITP), spinal cord stimulators (SCS), and peripheral nerve stimulators (PNS) used in the treatment of chronic pain. There is less information, however, on the perioperative complications of these procedures.
Objective: Exploration of the perioperative outcomes of implantable pain devices.